MédiMabs is recognized and solicited for the personalized services they offer for the development of monoclonal antibodies. MédiMabs’ aim is to generate antibodies that recognize not only the immunizing agent but the entire target protein so as to ensure it functions in client’s application in the most satisfactory manner.
MédiMabs’ standard protocol for monoclonal antibodies production requires approximately 4 to 6 months to be completed. The process is divided in 4 phases with phase 2 being the Go/No Go phase at which point the project can be aborted should the pre-fusion screening does not meet client’s expectations.
Due the lack of a suitable fusion partner, rabbit monoclonal antibodies are much more difficult to develop compared to mouse or rat’s. MédiMabs circumscribes this problem by offering the Recombinant Monoclonal Antibody Technology (RMAT). This innovative technology screens the immune repertoire of the rabbit creating the power to select the desired antibody directly from B cells.
The RMAT technology provides: